Advanced glycation end-products and the kidney. - Wikidata - awgldk - TriplyDB

Advanced glycation end-products and the kidney.

Advanced glycation end-products and the kidney.

http://www.wikidata.org/entity/Q37774697

about

Role of Neuropilin-1 in Diabetic Nephropathy Advanced glycation end-products: modifiable environmental factors profoundly mediate insulin resistance Development of nonalcoholic hepatopathy: contributions of oxidative stress and advanced glycation end products Diabetic nephropathy and extracellular matrix Advanced glycated end-products affect HIF-transcriptional activity in renal cells Lifestyle and clinical determinants of skin autofluorescence in a population-based cohort study The effect of an AGE-rich dietary extract on the activation of NF-κB depends on the cell model used.A receptor-based bioadsorbent to target advanced glycation end products in chronic kidney disease.Potential Role of Serum and Urinary Biomarkers in Diagnosis and Prognosis of Diabetic Nephropathy.Skin autofluorescence and all-cause mortality in stage 3 CKD.Global renal gene expression profiling analysis in B2-kinin receptor null mice: impact of diabetes A glimpse of matrix metalloproteinases in diabetic nephropathy.Genomic damage in endstage renal disease-contribution of uremic toxins Garrod's fourth inborn error of metabolism solved by the identification of mutations causing pentosuria Periodontitis predicts elevated C-reactive protein levels in chronic kidney disease Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy Skin Autofluorescence in Systemic Sclerosis Is Related to the Disease and Vascular Damage: A Cross-Sectional Analytic Study of Comparative Groups ATP synthase subunit-β down-regulation aggravates diabetic nephropathy.High-mobility group box 1 inhibits HCO(3)(-) absorption in medullary thick ascending limb through a basolateral receptor for advanced glycation end products pathway Mechanisms of bradykinin-induced expression of connective tissue growth factor and nephrin in podocytes.Renal protection of in vivo administration of tempol in streptozotocin-induced diabetic rats.AGE-LDL activates Toll like receptor 4 pathway and promotes inflammatory cytokines production in renal tubular epithelial cells.Increased Burden of Vision Impairment and Eye Diseases in Persons with Chronic Kidney Disease - A Population-Based Study.sRAGE and risk of diabetes, cardiovascular disease, and death Insights into the Mechanisms Involved in the Expression and Regulation of Extracellular Matrix Proteins in Diabetic Nephropathy.Effects of Averrhoa carambola L. (Oxalidaceae) juice mediated on hyperglycemia, hyperlipidemia, and its influence on regulatory protein expression in the injured kidneys of streptozotocin-induced diabetic mice.Targeting of receptor for advanced glycation end products suppresses cyst growth in polycystic kidney disease.Cellular and molecular mechanisms of diabetic glomerulopathy.Pathophysiology of the diabetic kidney.AGEs, contributors to placental bed vascular changes leading to preeclampsia.Emerging role of post-translational modifications in chronic kidney disease and cardiovascular disease.Advanced glycation end products induce the apoptosis of and inflammation in mouse podocytes through CXCL9-mediated JAK2/STAT3 pathway activation.Advanced glycation end products (AGEs) increase renal lipid accumulation: a pathogenic factor of diabetic nephropathy (DN)The metabolic syndrome and chronic kidney disease.Progression of skin autofluorescence of AGEs over 4 years in patients with type 1 diabetes.Advanced glycation end products dietary restriction effects on bacterial gut microbiota in peritoneal dialysis patients; a randomized open label controlled trial.Serum methylglyoxal level and its association with oxidative stress and disease severity in patients with psoriasis.Binding of glycated ovocystatin to rat renal brush border membranes.Reference values of skin autofluorescence as an estimation of tissue accumulation of advanced glycation end products in a general Slovak population.Actin cytoskeletal rearrangement and dysfunction due to activation of the receptor for advanced glycation end products is inhibited by thymosin beta 4.

P2860

Q26799448-B10788D4-CC92-4A8D-93F9-402D75080E5F Q26800114-DB53FEBC-2F2F-46C1-968F-BC53723A42ED Q26861308-6BF5E6EF-74EB-4F93-A646-A25FF9D0A4B2 Q26996008-6C96D9BF-633F-48DA-8147-E0E10373F6BF Q28591845-CF6C0C39-26DC-43F2-8693-B059ED26CCB6 Q28595700-B3D38F82-3B7F-4479-A4E4-DE7A56D5C305 Q30317876-F1A401E3-FB6F-4DAE-9859-ADA2E319E9B6 Q33594667-C7014996-01BE-4FA8-BF65-FF513129451E Q33772238-91833337-3212-4E33-B7AB-05213F5858FD Q34008927-1B351956-777D-463E-AB2C-E0DDCA2DE96C Q34427292-8D39FF66-8D69-45C5-9575-E873158BB2B3 Q34796034-5404F34A-F7A2-404B-B992-919676108DDF Q35155634-C3B1F21D-B90E-4D59-B3D9-82A3BDBF0B3F Q35546663-F6203DC9-6F4C-4B6E-AC67-8AF62FD1D702 Q35549017-047450B8-47AB-43B8-932B-4AF7A9CD8E2C Q35673446-CAEB534D-992D-4E15-B5A0-DC3DA67B5AF0 Q35924733-B8D3077B-7A42-41C5-92B0-18C3AA12EC34 Q36139285-B280094D-645C-4D7B-B1A3-A6CB487A9D38 Q36174486-39061169-F0A1-4240-82EE-1BE2108C5D2E Q36345943-48BBE123-8204-46E7-9F21-12F071259022 Q36517099-3466564B-AA18-48F2-84F1-95AF8FAD0EE2 Q36562734-905B5316-65DB-41F4-9EDF-6A0ACC82502B Q36753936-2F631A0A-9409-4954-A054-CC0D3AA04F6A Q36867450-6E559B3F-CB90-4D0E-A94D-2CD23972BEDB Q36891626-19EA65CF-D257-4B29-B05E-72920205C101 Q37596859-68261E86-5B97-4085-8F67-65CAB21AA09D Q37691594-8728C0F6-D9D2-4C7C-8581-94B6698B7ADF Q38010045-29B9A248-FE14-4E50-9947-68BC891833FE Q38111707-5899BC3B-C042-4D6A-949D-A7826D2A3659 Q38116590-770345EF-E98F-4220-86BA-44F3A0984273 Q38415749-CC3AD67F-CB79-4FDD-A91B-0972540A0BC6 Q38604519-6A40C317-0AC1-4752-A794-F612110B945C Q38698725-38D8054B-8726-4CD2-8159-426DB1BFAEBA Q39056509-82C1CD9A-EDFC-4ED8-B2D3-119E44F5D0E3 Q40118617-F9BA38F3-25B4-407D-86E8-9D3C5683EA7A Q41836455-210DDBA6-5301-4B81-ACDB-6C5B1B567870 Q44654649-CF95CC9F-5B42-4EC7-BAED-3B14DFD004A8 Q45342885-0A540ED2-8DBF-4E6B-9B1B-0684D3C8830D Q45970190-B9FEC13B-0A98-43BC-BD4F-BDBF64C348C8 Q46779205-93BD474D-2F77-4A4A-B2CC-B46F7766F5F4

P2860

Advanced glycation end-products and the kidney.

http://www.wikidata.org/entity/Q37774697

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on August 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Advanced glycation end-products and the kidney.

@en

Advanced glycation end-products and the kidney.

@nl

type

label

Advanced glycation end-products and the kidney.

@en

Advanced glycation end-products and the kidney.

@nl

prefLabel

Advanced glycation end-products and the kidney.

@en

Advanced glycation end-products and the kidney.

@nl

P1433

Q37774697-7B253A43-6BE1-4DB7-B8B4-0A2BB4E04F66

P1476

Q37774697-A27BBF1A-EB4E-4EED-861D-32C520982952

P2093

Q37774697-2E252726-36C6-47B8-9DFD-5F81FC95604C

Q37774697-716D39AA-AF2E-4D32-B1A1-AB2454EAFC2E

Q37774697-847081AB-BE8D-4A8B-B0D9-CDAE70E49DC1

Q37774697-FC5BCB73-5286-4DD1-B5F3-8FA113802FF0

P2860

Q37774697-0063A073-34F0-4320-A10E-9693FB40367B

Q37774697-38EBFA81-ED31-4498-8A67-B145A4BB25D5

Q37774697-408B34AF-9AB6-4F27-8A94-3A92783F40DC

Q37774697-44AB820C-10F3-4DC3-B66B-C1D42A5F9118

Q37774697-64345B97-CE4E-482E-97F0-E3B7FBD69711

Q37774697-7B7BE9B3-9136-461B-91BC-6B44D1E77092

Q37774697-8AEFFBFC-5EF6-462D-8EF8-DBF69F3C7EC8

Q37774697-8F2C1A7F-4B1D-4BE0-9267-5C13D9A02E1E

Q37774697-E1B92694-7CFF-453D-9E5E-841D6C73402B

P304

Q37774697-192F3174-A935-4D1D-9A1A-B70F85A9360D

P31

Q37774697-181DC03C-E5C4-47CA-8729-3C17D56E02B6

P356

Q37774697-EEB6C9AF-BD0A-4B90-978D-7AAEF3B24A41

P433

Q37774697-00B1854C-B0A9-40D7-BC72-4C566DE743B6

P478

Q37774697-E51F6A38-DFCE-4F47-A009-D8DECA88CD34

P577

Q37774697-9C0BC2A5-DBBD-4A83-96D4-5532668C8B7C

P5875

Q37774697-FAB1B002-8D3C-4B1F-86E8-0FFF3F415226

P698

Q37774697-0513CF5B-3273-448D-9AD8-9FF439BE9F78

P356

J.1365-2362.2010.02317.X

P1433

European Journal of Clinical Investigation

P1476

Advanced glycation end-products and the kidney.

@en

P2093

Christiane Rüster

http://www.w3.org/2001/XMLSchema#string

Gunter Wolf

http://www.w3.org/2001/XMLSchema#string

Martin Busch

http://www.w3.org/2001/XMLSchema#string

Sybille Franke

http://www.w3.org/2001/XMLSchema#string

P2860

The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system

New biomarkers of Maillard reaction damage to proteins.

The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses.

Protein and nucleotide damage by glyoxal and methylglyoxal in physiological systems--role in ageing and disease.

Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response.

RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy.

Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.

Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients. A prospective study.

Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease.

P304

742-755

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2362.2010.02317.X

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45280715

http://www.w3.org/2001/XMLSchema#string

P698

20649640

http://www.w3.org/2001/XMLSchema#string